drugset / Trial / NCT00665327
Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study was to assess the safety of sequential intravenous (IV)/oral (PO) moxifloxacin (Avelox®) compared with sequential IV/PO levofloxacin (Levaquin®) in the treatment of elderly subjects (aged \≥ 65 years) with community-acquired pneumonia (CAP) who required initial IV therapy. This study also included an assessment of the clinical and bacteriologic effectiveness of both drugs.
Timeline
- Start
- 2002-11
- Primary completion
- 2004-04
- Completion
- 2004-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Levofloxacin | Small molecule | 250 mg | Intravenous |
| Comparator | Levofloxacin | Small molecule | 500 mg | Intravenous |
| Subject | Moxifloxacin | Small molecule | 400 mg | Intravenous |